Cardiff Oncology announces updated Phase 2 mCRPC data and preclinical ovarian cancer data for onvansertib

Cardiff Oncology, Inc.

Arm C (12 mg/m2 onvansertib days 1-14) achieved 75% radiographic stable disease at 12 weeks vs 53% in Arm A.
Median progression-free survival increased from 4.1 months in Arm A to 13.2 months to-date in Arm C.
Combination of onvansertib with olaparib overcame PARP inhibitor resistance in BRCA1-mutant and wildtype PDX ovarian cancer models.
Mutations in PTEN and MTOR were positively associated with treatment response in mCRPC trial patients.
Disease control by PSA stabilization improved from 29% in Arm A to 45% in Arm C.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.